The effect of vitamin D supplementation on premenstrual syndrome(PMS)

The effect of vitamin D supplementation on inflammation and antioxidant markers and premenstrual syndrome(PMS) symptoms in vitamin D- deficient students

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180525039822N1

Enrollment

Registered

2018-06-20

Start date

2017-12-22

Completion date

Unknown

Last updated

2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

premenstrual syndrome.

Interventions

Intervention 1: Intervention group: An oral supplement of 50,000 units of vitamin D from Tabriz's Zahrawi Company during 4 menstrual cycles every two weeks. Intervention 2: Control group: Receiving a

Eligibility

Sex/Gender

Female

Age

18 Years to 25 Years

Inclusion criteria

Inclusion criteria: Age of 25-18 years BMI in normal range single Serum vitamin D level is 30- 10 ng / ml Having a regular menstrual cycle with intervals of 35 to 21 days Not doing regular exercise Students do not start or finish their studies in the semester

Exclusion criteria

Exclusion criteria: Acute and chronic diseases such as: cardiovascular, kidney, liver, diabetes, hypothyroidism, hyperthyroidism and asthma Iron deficiency anemia (Anemia) Depression and anxiety Consumption of combined pills containing estrogen and progesterone Take supplemental vitamin D in the last 3 months

Design outcomes

Primary

Measure	Time frame
Serum level of interleukin 10 based on ELISA method. Timepoint: At the beginning of the study and after 4 months of intervention. Method of measurement: Blood sampling and serum level determination using ELISA kit.;Serum level of interleukin 12 based on ELISA method. Timepoint: At the beginning of the study and after 4 months of intervention. Method of measurement: Blood sampling and serum level determination using ELISA kit.;Serum level of total antioxidant capacity based on ELISA method. Timepoint: At the beginning of the study and after 4 months of intervention. Method of measurement: Blood sampling and serum level determination using ELISA kit.;Score of physical symptoms and mood syndrome in premenstrual syndrome in the symptom registration questionnaire. Timepoint: At the beginning of the study and after 4 months of intervention. Method of measurement: Premenstrual Signs Indexing Questionnaire (DSM-IV).	—

Measure

Time frame

Serum level of interleukin 10 based on ELISA method. Timepoint: At the beginning of the study and after 4 months of intervention. Method of measurement: Blood sampling and serum level determination using ELISA kit.;Serum level of interleukin 12 based on ELISA method. Timepoint: At the beginning of the study and after 4 months of intervention. Method of measurement: Blood sampling and serum level determination using ELISA kit.;Serum level of total antioxidant capacity based on ELISA method. Timepoint: At the beginning of the study and after 4 months of intervention. Method of measurement: Blood sampling and serum level determination using ELISA kit.;Score of physical symptoms and mood syndrome in premenstrual syndrome in the symptom registration questionnaire. Timepoint: At the beginning of the study and after 4 months of intervention. Method of measurement: Premenstrual Signs Indexing Questionnaire (DSM-IV).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHajar Heidari

Esfahan University of Medical Sciences

h.heidari72@ymail.com+98 31 4262 5779

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 1, 2026